Treatment with MK6592 and an anti-cancer drug (docetaxel) in patients with advanced solid tumors

Trial Profile

Treatment with MK6592 and an anti-cancer drug (docetaxel) in patients with advanced solid tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs MK 6592 (Primary) ; Antineoplastics
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 13 Nov 2007 Status changed from recruiting to discontinued
    • 08 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top